134 related articles for article (PubMed ID: 2545499)
1. Antipyrine clearance per unit liver volume in cirrhotics with and without hepatocellular carcinoma indicating a correlation with histological change of the liver.
Noda S; Kawata S; Miyoshi S; Minami Y; Tarui S
Gastroenterol Jpn; 1989 Apr; 24(2):159-63. PubMed ID: 2545499
[TBL] [Abstract][Full Text] [Related]
2. Antipyrine clearance in chronic and neoplastic liver diseases: a study of 518 patients.
Grieco A; Castellano R; Matera A; Marcoccia S; Di Rocco P; Ragazzoni E; Vecchio FM; Gasbarrini G
J Gastroenterol Hepatol; 1998 May; 13(5):460-6. PubMed ID: 9641640
[TBL] [Abstract][Full Text] [Related]
3. Caffeine clearance study in hepatocellular carcinoma.
Tangkijvanich P; Wittayalertpanya S; Kusonsolboon T; Thong-Ngam D; Mahachai V
J Med Assoc Thai; 1999 Mar; 82(3):297-303. PubMed ID: 10410486
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver.
Preiss R; Matthias M; Sohr R; Brockmann B; Hüller H
J Cancer Res Clin Oncol; 1987; 113(6):593-8. PubMed ID: 2824523
[TBL] [Abstract][Full Text] [Related]
5. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
[TBL] [Abstract][Full Text] [Related]
6. Antipyrine metabolism in patients with liver metastases from colorectal cancer.
Grieco A; Barone C; Coletta P; Castellano R; Ragazzoni E; Cassano A; Astone A; Gambassi G
Cancer; 1992 Sep; 70(6):1477-82. PubMed ID: 1515999
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of antipyrine clearance in chronic liver diseases].
Wang JL; Zhang F; Yuan SY
Zhonghua Nei Ke Za Zhi; 1989 May; 28(5):295-7, 315-6. PubMed ID: 2553353
[TBL] [Abstract][Full Text] [Related]
8. Galactose loading tests in patients with hepatocellular carcinoma for the assessment of chemotherapy.
Buzzelli G; Meacci E; Smorlesi C; Chiarantini E; Birardi A; Gentilini P
Chemioterapia; 1987 Aug; 6(4):306-9. PubMed ID: 2820595
[TBL] [Abstract][Full Text] [Related]
9. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
[TBL] [Abstract][Full Text] [Related]
10. A comparison between antipyrine and aminopyrine blood clearances.
Kawasaki S; Imamura H; Kokudo N; Bandai Y; Sanjo K; Idezuki Y
Hepatogastroenterology; 1992 Aug; 39(4):344-6. PubMed ID: 1427580
[TBL] [Abstract][Full Text] [Related]
11. Hepatic parenchymal cell volume and the indocyanine green tolerance test.
Hashimoto M; Watanabe G
J Surg Res; 2000 Aug; 92(2):222-7. PubMed ID: 10896825
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia inducible factor 1α in hepatocellular carcinoma with cirrhosis: Association with prognosis.
Wang D; Zhang X; Lu Y; Wang X; Zhu L
Pathol Res Pract; 2018 Dec; 214(12):1987-1992. PubMed ID: 30274686
[TBL] [Abstract][Full Text] [Related]
13. Assessment of oxidative metabolism in adults with hepatocellular carcinoma in the Sudan.
Homeida MM; Daneshmend TK; Ali EM; Yousif-Elkadaru AG; Arbab BM
Gut; 1986 Apr; 27(4):382-5. PubMed ID: 3007307
[TBL] [Abstract][Full Text] [Related]
14. DNA synthesis activities of hepatocytes from noncancerous cirrhotic tissue and of hepatocellular carcinoma (HCC) cells from cancerous tissue can predict the survival of hepatectomized patients with HCC.
Tarao K; Ohkawa S; Shimizu A; Harada M; Nakamura Y; Okamoto N; Ito Y; Tamai S; Iimori K; Sugimasa Y
Cancer; 1993 Jun; 71(12):3859-63. PubMed ID: 8389652
[TBL] [Abstract][Full Text] [Related]
15. Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease.
Krausz Y; Zylber-Katz E; Levy M
Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):253-7. PubMed ID: 7450926
[TBL] [Abstract][Full Text] [Related]
16. Liver cell dysplasia in normal, cirrhotic, and hepatocellular carcinoma patients.
Cohen C; Berson SD
Cancer; 1986 Apr; 57(8):1535-8. PubMed ID: 3004693
[TBL] [Abstract][Full Text] [Related]
17. Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression.
Coverdale SA; Samarasinghe DA; Lin R; Kench J; Byth K; Khan MH; Crewe E; Liddle C; George J; Farrell GC
Am J Gastroenterol; 2003 Jun; 98(6):1384-90. PubMed ID: 12818285
[TBL] [Abstract][Full Text] [Related]
18. Liver cell dysplasia in association with hepatocellular carcinoma, cirrhosis and hepatitis B surface antigen in Hong Kong.
Ho JC; Wu PC; Mak TK
Int J Cancer; 1981 Nov; 28(5):571-4. PubMed ID: 6273339
[TBL] [Abstract][Full Text] [Related]
19. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver.
Turlin B; Juguet F; Moirand R; Le Quilleuc D; Loréal O; Campion JP; Launois B; Ramée MP; Brissot P; Deugnier Y
Hepatology; 1995 Aug; 22(2):446-50. PubMed ID: 7635411
[TBL] [Abstract][Full Text] [Related]
20. [Expression and its clinicopathological features of tumor rejective antigen 1 in human tissues of hepatocellular carcinoma and liver cirrhosis].
Zhang H; Huang DF; Wei Q; Hua TY; Li F; Huang JF
Zhonghua Gan Zang Bing Za Zhi; 2010 Sep; 18(9):661-5. PubMed ID: 20943076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
